AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$NBIX

Bernstein reiterates Neurocrine Bio stock rating on Crenessity beat

Bernstein reiterated an Outperform rating and $218 price target on Neurocrine Biosciences (NBIX) after its Q3 2026 earnings beat estimates. Revenue was $1.12B, up 41% YoY, with Crenessity sales at $211M. Analysts highlight strong drug performance and growth momentum. Other firms also raised price targets.

Original reporting
investing.com
Published Nov 4, 2026, 2:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NBIX
Bullish
high confidence
Mentioned
$NBIX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NBIXBullishHigh
01

Why it matters

Earnings beat and target raises could drive short‑term buying interest.

02

Market read

New earnings data and analyst upgrades provide a fresh catalyst for NBIX.

03

What to watch

Potential headwinds from regulatory scrutiny of neuro‑psychiatric drugs are not discussed.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

The article summarizes Neurocrine's Q3 earnings release and analyst rating actions.

Company-level read

Ticker impact

$NBIXBullishHigh confidence
Context

Neurocrine Biosciences reported Q3 2026 earnings beating revenue and EPS estimates, prompting analysts to reiterate Outperform ratings and raise price targets.

Expected impact

likely upside as the market prices in the earnings beat and higher price targets

Evidence & confidence

Revenue of $1.12B (+41% YoY) and EPS of $1.96 beat consensus; multiple analysts raised targets to $215‑$224, indicating strong investor demand.

Market effects

Sector

Strong performance may boost sentiment in the biotech sector and related neuro‑pharma stocks.

Regional

U.S. biotech market likely sees modest gains.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

Some investors may view the high valuation multiples as overhyped despite the beat.

Key entities

  • company
    Neurocrine Biosciences Inc.

    Biotech firm reporting Q3 earnings.

  • analyst
    Bernstein

    Reiterated Outperform rating with $218 target.

Read at source← All news

StoryNeurocrine Biosciences posts record Q3 2026 revenue and raises Ingrezza guidance

Also covered by

6 outlets

Related articles

NOV 3
$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com2 min
NOV 3
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com2 min
NOV 3
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com2 min